Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Daryl Pritchard"'
Autor:
Helen Sadik, Daryl Pritchard, Derry-Mae Keeling, Frank Policht, Peter Riccelli, Gretta Stone, Kira Finkel, Jeff Schreier, Susanne Munksted
Publikováno v:
JCO Precision Oncology.
PURPOSE Personalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into cl
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(12)
Purpose Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (
Publikováno v:
JCO precision oncology. 6
PURPOSE In the era of personalized medicine, physicians rely on their understanding of clinical utility to assess the value of rapidly evolving genetic and genomic tests. Current definitions of the clinical utility of genetic testing sufficiently cap
Autor:
Monica M, Schroll, Arushi, Agarwal, Olivia, Foroughi, Emily, Kong, Omar, Perez, Daryl, Pritchard, Tom, Breur, Kristen, Garner Amanti, Gary, Gustavsen
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 7; Pages: 1025
Despite evidence that precision medicine (PM) results in improved patient care, the broad adoption and implementation has been challenging across the United States (US). To better understand the perceived barriers associated with PM adoption, a quant
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 196, p 196 (2021)
Journal of Personalized Medicine
Volume 11
Issue 3
Journal of Personalized Medicine
Volume 11
Issue 3
Personalized medicine (PM) approaches have revolutionized healthcare delivery by offering new insights that enable healthcare providers to select the optimal treatment approach for their patients. However, despite the consensus that these approaches
Publikováno v:
Clinical lung cancer. 21(6)
Two recent studies examining the clinical and economic value of next-generation sequencing (NGS)-based diagnostic testing (multi-gene panel examining ≥ 30 genes) for non–small-cell lung cancer therapy compared with single gene ALK, EGFR testing t
Publikováno v:
The American journal of managed care. 25(11)
Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.
Autor:
Bernardo H. L. Goulart, Neal J. Meropol, Daryl Pritchard, Lotte Maria Gertruda Steuten, Scott D. Ramsey
Publikováno v:
JCO clinical cancer informatics. 3
PURPOSE Compared with single-marker genetic testing (SMGT), multigene panel sequencing (MGPS) has the potential to identify more patients with cancer who could benefit from targeted therapies, but the effects on outcome and total cost of care are unc
Publikováno v:
Health affairs (Project Hope). 37(5)
Despite rapid advances in molecular diagnostics and targeted therapeutics, the adoption of precision medicine into clinical oncology workflows has been slow. Questions about clinical utility, inconsistent reimbursement for molecular diagnostics, and
Autor:
Bonnie J, Addario, Daryl, Pritchard
Publikováno v:
The American journal of managed care. 23(10 Spec)